Posted by Michael Wonder on 04 Nov 2023
Elexacaftor with tezacaftor and ivacaftor, tezacaftor with ivacaftor and lumacaftor with ivacaftor for the treatment of patients with cystic fibrosis
3 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of elexacaftor with tezacaftor and ivacaftor, tezacaftor with ivacaftor and lumacaftor with ivacaftor in the NHS in England.
For the time being, elexacaftor with tezacaftor and ivacaftor (Kaftrio) is not recommended for use in combination with ivacaftor for the treatment of patients 6 years and over with cystic fibrosis who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene.
For the time being, tezacaftor with ivacaftor (Symkevi) is not recommended for use in combination with ivacaftor for the treatment of certain patients aged 6 years and over with cystic fibrosis.
For the time being, lumacaftor with ivacaftor (Orkambi) is not recommended for the treatment of patients 1 year and over with cystic fibrosis who have 2 copies of the CFTR gene with a F508del mutation.
